AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29099333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor alone
Number of subjects: 248
Study 29099333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 25599107 — intervention group
Group type: COMPARATOR
Intervention: Baseline testing with Wechsler Intelligence Scale for Children‐‐Fourth Edition Short Form (WISC‐IV‐SF) and Delis‐Kaplan Executive Function System (D‐KEFS) subtests; Re-assessment 20 ±2 weeks later with shortened test battery including D‐KEFS subtests, Digit Span, Coding and Symbol Search (WISC‐IV), and BRIEF
Number of subjects: 44
Study 23343320 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM (Adapted Intervention Mapping)
Number of subjects: 10
Study 23343320 — intervention group
Group type: COMPARATOR
Intervention: School Health Index (SHI)
Number of subjects: 10
Study 21862719 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG biomarkers (477 total, 14 identified as predictive of long-term mortality)
Number of subjects: 33144
Study 21862719 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation subset (n=22,096; deaths, 819)
Number of subjects: 33144
Study 21862719 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation subset (n=11,048; deaths, 410)
Number of subjects: 33144
Study 19489489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziwu Liuzhu group (n=95)
Number of subjects: 190
Study 19489489 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture group (n=95)
Number of subjects: 190
Study 17185122 — intervention group
Group type: EXPERIMENTAL
Intervention: CDF + 1
Number of subjects: 100
Study 17185122 — intervention group
Group type: EXPERIMENTAL
Intervention: CDF + 2
Number of subjects: 100
Study 17185122 — intervention group
Group type: EXPERIMENTAL
Intervention: CDF + 3
Number of subjects: 100
Study 17185122 — intervention group
Group type: COMPARATOR
Intervention: Positive controls
Number of subjects: 100
Study 17185122 — intervention group
Group type: COMPARATOR
Intervention: Negative controls
Number of subjects: 100
Study 17185122 — intervention group
Group type: EXPERIMENTAL
Intervention: SEM observation
Number of subjects: 100
Study 15505069 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal surgery combined with simultaneous transplantation of autologous retinal pigment epithelial (RPE) cells (group 1)
Number of subjects: 53
Study 15505069 — intervention group
Group type: COMPARATOR
Intervention: Membrane excision alone (group 2)
Number of subjects: 53
Study 15505069 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal surgery with RPE transplantation (group 1)
Number of subjects: 53
Study 15221294 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-SPECT/CT imaging
Number of subjects: 71
Study 11061521 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 9
Study 9411344 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulant containing lyophilized bacterial extracts
Number of subjects: 68
Study 9411344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8398831 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor IX concentrate
Number of subjects: 6
Study 8398831 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 6
Study 2939682 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid premedication (midazolam)
Number of subjects: 18
Study 2939682 — intervention group
Group type: COMPARATOR
Intervention: Opioid premedication (papaveretum)
Number of subjects: 18
Study 2801064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low dose heparin (5.000 IU) and dihydroergotamine (0.5 mg) given subcutaneously every twelve hours (n = 27)
Number of subjects: 55
Study 2801064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 55
Study 31858145 — intervention group
Group type: COMPARATOR
Intervention: Approach #1: Assume SFOL = 0
Number of subjects: 0
Study 31858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach #2: Impute SFOL (population median)
Number of subjects: 0
Study 31858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach #3: Impute Hct (population median)
Number of subjects: 0
Study 31858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach #4: Estimate Hct (Hb/MCHC)
Number of subjects: 0
Study 31858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach #5: Assume SFOL = 0 and estimate Hct
Number of subjects: 0
Study 31858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach #6: Predict SFOL (from WBF) and estimate Hct
Number of subjects: 0
Study 31125095 — intervention group
Group type: EXPERIMENTAL
Intervention: modMBSR
Number of subjects: 21
Study 31125095 — intervention group
Group type: COMPARATOR
Intervention: active control
Number of subjects: 21
Study 27632530 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training program (special nonsense-syllables with background noise), 3 weeks, twice a week for 1 hour
Number of subjects: 46
Study 27632530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 46
Study 27632530 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up measurement 2-3 months after training
Number of subjects: 46
Study 26001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during resting tidal breathing (RTB)
Number of subjects: 24
Study 26001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during postexercise breathing (PEB)
Number of subjects: 24
Study 26001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during recovery breathing (RB)
Number of subjects: 24
Study 26001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 24
Study 22682547 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics investigation by cystometrogram, uroflowmetry and electromyogram (UFM/EMG)
Number of subjects: 56
Study 22682547 — intervention group
Group type: COMPARATOR
Intervention: Pressure/flow/EMG (P/F/EMG) studies
Number of subjects: 56
Study 22682547 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics (general)
Number of subjects: 56
Study 22682547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha adrenergic blockers
Number of subjects: 56
Study 21376892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal flight (search for a target on the ground)
Number of subjects: 0
Study 21376892 — intervention group
Group type: EXPERIMENTAL
Intervention: Last-minute reminder about the mandated minimum altitude
Number of subjects: 0
Study 19724889 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine administration (1.5 g and 3 g/day for 3 months)
Number of subjects: 0
Study 19724889 — intervention group
Group type: COMPARATOR
Intervention: Non-athlete controls
Number of subjects: 0
Study 19724889 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer players
Number of subjects: 0
Study 17179022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg oral dose)
Number of subjects: 13
Study 15573244 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive bupivacaine infiltration (Marcaine) before incision and into muscle layer after incision
Number of subjects: 123
Study 15573244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 123
Study 11765110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' involvement in health care delivery
Number of subjects: 13
Study 11765110 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling by pharmacists
Number of subjects: 13
Study 11765110 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with patients' physicians
Number of subjects: 13
Study 11765110 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to patient-specific clinical data
Number of subjects: 13
Study 11765110 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles to implementing pharmaceutical care programs
Number of subjects: 13
Study 9885752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciloxan
Number of subjects: 21
Study 9885752 — intervention group
Group type: EXPERIMENTAL
Intervention: Siprogut
Number of subjects: 21
Study 8007810 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrained breathing (inspire during drive, expire during recovery; expire during drive, inspire during recovery)
Number of subjects: 16
Study 8007810 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 16
Study 2699468 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 56145 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivates of gelatin
Number of subjects: 750
Study 56145 — intervention group
Group type: COMPARATOR
Intervention: Macrodex and Plasmasteril combined
Number of subjects: 750
Study 56145 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 750
Study 56145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelifundol-S
Number of subjects: 750
Study 56145 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrodex
Number of subjects: 750
Study 56145 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-Plasmagel
Number of subjects: 750
Study 31603191 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy (according to maximum aggregation rate); if MAR > 55%, 90 mg ticagrelor twice daily plus 100 mg/day aspirin; if MAR ≤ 55%, 75 mg/day clopidogrel plus 100 mg/day aspirin
Number of subjects: 2237
Study 31603191 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet treatment (75 mg/day clopidogrel plus 100 mg/day aspirin for at least 6 months)
Number of subjects: 2237
Study 31603191 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy
Number of subjects: 2237
Study 31603191 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet treatment
Number of subjects: 2237
Study 31242860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B deoxycholate 0.7-1.0 mg/kg/day for induction therapy
Number of subjects: 696
Study 31242860 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to minimize/prevent phlebitis: 1 liter of IV normal saline after each dose, rotating IV catheters every three days, infusing IV amphotericin over 4 hours, encouraging early ambulation
Number of subjects: 696
Study 31242860 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compresses, topical diclofenac gel, and oral anti-inflammatory medicines for severe cases
Number of subjects: 696
Study 27989017 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1 wt% S-PRG
Number of subjects: 180
Study 27989017 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5 wt% S-PRG
Number of subjects: 180
Study 27989017 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 20 wt% S-PRG
Number of subjects: 180
Study 27989017 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1500 ppm fluoride as sodium monofluorophosphate (NaMFP)
Number of subjects: 180
Study 27989017 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing 0 wt% S-PRG
Number of subjects: 180
Study 25955443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii (web-based therapy programme) for 20 weeks
Number of subjects: 102
Study 25955443 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 102
Study 23731043 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 127
Study 22078342 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 100
Study 22078342 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anaesthesia (EA)
Number of subjects: 100
Study 19252962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day mindfulness and acceptance-based workshop targeting obesity-related stigma and psychological distress
Number of subjects: 84
Study 19252962 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 84
Study 17178968 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy
Number of subjects: 0
Study 15294364 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally every 4 h)
Number of subjects: 200
Study 15294364 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg intracervically every 6 h)
Number of subjects: 200
Study 11514956 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 14
Study 11514956 — intervention group
Group type: COMPARATOR
Intervention: Highly Active Antiretroviral Therapy (HAART)
Number of subjects: 14
Study 9569468 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-component pertussis combination vaccine (CPDT‐IPV//PRP‐T)
Number of subjects: 0
Study 9569468 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate injection of CPDT‐IPV and PRP‐T
Number of subjects: 0
Study 9569468 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis combination vaccine (DPT‐IPV//PRP‐T)
Number of subjects: 0
Study 9569468 — intervention group
Group type: EXPERIMENTAL
Intervention: Component vaccines (CPDT‐IPV)
Number of subjects: 0
Study 9569468 — intervention group
Group type: COMPARATOR
Intervention: Whole cell vaccine (DPT‐IPV)
Number of subjects: 0
Study 9569468 — intervention group
Group type: EXPERIMENTAL
Intervention: CPDT‐IPV//PRP‐T
Number of subjects: 0
Study 9569468 — intervention group
Group type: EXPERIMENTAL
Intervention: CPDT
Number of subjects: 0
Study 7915348 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 46
Study 7915348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3410154 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol administered from the Diskhaler (breath operated system)
Number of subjects: 42
Study 3410154 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol administered from the metered dose inhaler
Number of subjects: 42
Study 31235189 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFil Rock (zinc-reinforced glass-ionomer)
Number of subjects: 218
Study 31235189 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP (high-viscous glass-ionomer cement)
Number of subjects: 218
Study 28724170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IGF-1 levels (day 8)
Number of subjects: 404
Study 28724170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IGFBP-3 levels (day 8)
Number of subjects: 404
Study 27038550 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 300
Study 27038550 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 300
Study 27038550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27038550 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential Depression Treatment Response Index (DTRI)
Number of subjects: 300
Study 27038550 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers (DNA, RNA, plasma)
Number of subjects: 300
Study 27038550 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical moderators
Number of subjects: 300
Study 27038550 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological moderators and mediators
Number of subjects: 300
Study 24714008 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid/colloid combination (750 ml crystalloid and 250 ml colloid)
Number of subjects: 0
Study 24714008 — intervention group
Group type: COMPARATOR
Intervention: Colloid intravenous fluid preload (500 ml)
Number of subjects: 0
Study 21404369 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with multimodal behaviour therapy
Number of subjects: 45
Study 21404369 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 45
Study 21404369 — intervention group
Group type: COMPARATOR
Intervention: Matched normal control group
Number of subjects: 45
Study 21404369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 45
Study 19400874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 100 mg/day
Number of subjects: 108
Study 19400874 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg/day
Number of subjects: 108
Study 17334460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 2 mg/kg (Group K)
Number of subjects: 40
Study 17334460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol 3 mg/kg and intravenous fentanyl 1 microg/kg with propofol infusion of 1 mg/kg/hr (Group PF)
Number of subjects: 40
Study 14758299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg/dose, twice a day)
Number of subjects: 35
Study 14758299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11777112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Assault Risk Reduction Program
Number of subjects: 762
Study 11777112 — intervention group
Group type: COMPARATOR
Intervention: No-treatment comparison group
Number of subjects: 762
Study 9775459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) phenobarbital 10 micrograms/kg (n = 42 newborns)
Number of subjects: 100
Study 9775459 — intervention group
Group type: COMPARATOR
Intervention: Diluted distilled water (control group, n = 46 newborns)
Number of subjects: 100
Study 9775459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (not specified if in phenobarbital or control group)
Number of subjects: 100
Study 8092438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 261
Study 8092438 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 261
Study 3291140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic bone growth stimulator (EBGS)
Number of subjects: 416
Study 3291140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EBGS)
Number of subjects: 416
Study 3291140 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing nonrandomized study (I-B)
Number of subjects: 416
Study 30902908 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided care management led by PD nurses
Number of subjects: 328
Study 30902908 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 27016000 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00010 (50, 150, 400, 800 μg kg(‐1) in Part I; 400, 600, 1200 μg kg(‐1) in Part II)
Number of subjects: 28
Study 27016000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24652308 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat head-of-bed (HOB) positioning
Number of subjects: 17
Study 23794671 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 180 (DLT rotated 180°)
Number of subjects: 164
Study 23794671 — intervention group
Group type: COMPARATOR
Intervention: Group 90 (DLT rotated 90°)
Number of subjects: 164
Study 20839954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐PCNL
Number of subjects: 69
Study 20839954 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 69
Study 18801405 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid)
Number of subjects: 40
Study 18801405 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 40
Study 15959636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment for at least 6 months achieving a minimum distalization of 4 mm
Number of subjects: 86
Study 15959636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment
Number of subjects: 86
Study 15314975 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and Cisplatin (three courses)
Number of subjects: 0
Study 15314975 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who had not undergone inductive chemotherapy)
Number of subjects: 0
Study 10894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry (5 grams mixed in 150 mL of normal saline)
Number of subjects: 38
Study 10894097 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (1 unit per kilogram bodyweight mixed in 150 mL of normal saline)
Number of subjects: 38
Study 8895044 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg capsules once daily for 3 days)
Number of subjects: 759
Study 8895044 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablet three times daily for 5-10 days)
Number of subjects: 759
Study 8457082 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-heparin (12,500 IU/day, subcutaneous)
Number of subjects: 40
Study 8457082 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (250 mg/day, oral)
Number of subjects: 40
Study 3510602 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 242
Study 3510602 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide hydrochloride
Number of subjects: 242
Study 3510602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 29792485 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered, therapist-assisted bibliotherapy (TTB; n = 15)
Number of subjects: 31
Study 29792485 — intervention group
Group type: COMPARATOR
Intervention: Self-directed bibliotherapy (SB; n = 16)
Number of subjects: 31
Study 29792485 — intervention group
Group type: EXPERIMENTAL
Intervention: TTB
Number of subjects: 31
Study 29792485 — intervention group
Group type: COMPARATOR
Intervention: SB
Number of subjects: 31
Study 24470701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I), 4-week group-administered program
Number of subjects: 118
Study 22745675 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about willpower viewed as non-limited resource
Number of subjects: 0
Study 22745675 — intervention group
Group type: COMPARATOR
Intervention: Beliefs about willpower viewed as limited resource
Number of subjects: 0
Study 19902183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of rimonabant for 2 weeks
Number of subjects: 49
Study 19902183 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 49
Study 18049294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg twice daily
Number of subjects: 16